BRD9 controls the oxytocin signaling pathway in gastric cancer via CANA2D4, CALML6, GNAO1, and KCNJ5

BACKGROUND: First-line chemotherapeutic agents lead to remarkable activation treatment in cancers, but the side effects of these drugs also damage healthy cells. In some cases, drug resistance to chemotherapeutic agents is induced in cancer cells. The molecular mechanisms underlying such a side effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yuan, Jiang, Xue-Yan, Yu, Xi-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798819/
https://www.ncbi.nlm.nih.gov/pubmed/35117701
http://dx.doi.org/10.21037/tcr.2020.03.67

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798819/
https://www.ncbi.nlm.nih.gov/pubmed/35117701
http://dx.doi.org/10.21037/tcr.2020.03.67

Ejemplares similares